Koch Institute for Integrative Cancer Research

The Galien Foundation Honors 2023 Prix Galien Award Recipients

Retrieved on: 
Venerdì, Ottobre 27, 2023
American Cancer Society, Physiology, Medical genetics, Fred Hutchinson Cancer Research Center, Health technology, P. Roy Vagelos, Peace Corps, Incubator, University of Washington, NASA, Merck, Prix, Creativity, Tufts University School of Medicine, Koch Institute, Endeavour, MIT Jameel Clinic, Digital health, National Aeronautic Association, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Human Genome Sciences, African, ARD International Music Competition, Patient, Doctor of Philosophy, Nursing, Pharmaceutical industry, Biophysics, Biology

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year's award winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Product for Rare/Orphan Diseases," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity" and "Best Startup."

Key Points: 
  • "We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry," said Bruno Cohen, Chairman of The Galien Foundation.
  • "Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare."
  • The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement.
  • With chapters in 14 countries and Africa, and an inaugural chapter being established in India in 2024, Prix Galien is regarded worldwide as the equivalent of the Nobel Prize for the life science industry.

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Ovarian cancer, Bevacizumab, Patient, Research, Progression-free survival, SLL, Break, Koch Institute for Integrative Cancer Research, PFS, Gynecologic Oncology (journal), Koch Institute, DNA repair, Reproductive medicine, Clinical trial, MRD, Immunotherapy, University, Woman, Cancer, MD Anderson Cancer Center, Massachusetts Institute of Technology School of Engineering, Medical imaging

LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment. IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment.
  • IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study).
  • This Phase 1/2 trial is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer.
  • Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs. chemotherapy plus bevacizumab and IMNN-001.

Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

Retrieved on: 
Mercoledì, Settembre 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, SAB, Computational biology, Partnership, University, Malignancy, System, Immunoglobulin class switching, Immune tolerance, Howard Hughes Medical Institute, ETH Zurich, Cancer, MD Anderson Cancer Center, Cardiff University, Antibody, Doctor of Philosophy, Associate, TCR, Institute on Biotechnology and the Human Future, Professor, MD, Dartmouth University, Drug discovery, Protein engineering, Koch Institute for Integrative Cancer Research, Immunology, Therapy, Alloy, Cornell University, Chemical engineering, Peptide, Vaccine, Management, Fine chemical, Microbiology, Engineering

Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more.

Key Points: 
  • Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more.
  • “Alloy’s mission is to support our drug discovery partners by developing and providing broad access to innovative technologies and platforms.
  • Innovation and focus on quality drive our highly collaborative and science-focused R&D team,” explained Alloy President and Head of Research Piotr Bobrowicz, PhD.
  • Dr. Reddy previously co-founded deepCDR Biologics, a deep learning antibody discovery platform acquired by Alloy in December 2021.

City of Hope receives $100 million gift to create first-of-its-kind national integrative oncology program

Retrieved on: 
Martedì, Settembre 12, 2023
Volunteering, Survivor, City of Hope National Medical Center, City of Hope, Food, Drug development, Education, Culture, Society for Integrative Oncology, Panda Express, Cancer, Quality of life, Research, Koch Institute for Integrative Cancer Research, Pain, Panda Restaurant Group, Estate (law), Patient, Physician, Giant panda, LOS, Oncology, Health, Credit, Helen, Disease, Pharmaceutical industry, Hospital, Medical imaging, Nursing, City, Hope, Peggy Cherng

LOS ANGELES, Sept. 12, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced a $100 million gift from Andrew and Peggy Cherng, philanthropists, co-founders and co-CEOs of Panda Express, to create a first-of-its-kind, national integrative oncology program that brings together Eastern and Western medicine to improve outcomes and quality of life for cancer patients and survivors.  

Key Points: 
  • Integrative oncology is a whole-person approach to cancer care that draws from diverse cultures, particularly traditional Chinese medicine and other Eastern healing traditions.
  • City of Hope will make integrative oncology an evidence-based, interwoven standard of care that supports optimal cancer treatment and survivorship.
  • Within the next year, City of Hope plans to create one of the first integrative oncology fellowships created and led by oncologists.
  • The benefits of integrative oncology will then be extended to patients throughout City of Hope's national cancer care and research system.

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"

Retrieved on: 
Giovedì, Luglio 27, 2023
Heart, Tufts University School of Medicine, University, Doctor of Philosophy, Fred Hutchinson Cancer Research Center, MIT Jameel Clinic, University of Washington, Human Genome Sciences, Koch Institute, Merck, American Cancer Society, Koch Institute for Integrative Cancer Research, Medical genetics, Physiology, Pharmaceutical industry, Biophysics, Biology

NEW YORK, July 27, 2023 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2023 Prix Galien USA Award nominees for "Best Biotechnology Product", and "Best Pharmaceutical Product." Nominees have also been announced in the newest Prix Galien Award category, "Best Product for Rare/Orphan Diseases." Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2023, at the American Museum of Natural History in New York City. 

Key Points: 
  • "The annual Prix Galien USA Awards provide the opportunity to recognize the incredible achievements of those at the forefront of healthcare innovation, which have become the backbone of many biomedical and technology advances," said Bruno Cohen, Chairman of The Galien Foundation.
  • "We look forward to honoring the most impactful innovations of our generation, center stage, in the heart of New York City."
  • The Prix Galien USA Awards Committee is composed of 11 renowned leaders from the biomedical industry and academia, including three Nobel Laureates, responsible for evaluating nominees.
  • M.D., Former Dean of Tufts University School of Medicine, and former Chief Medical Officer of Merck & Co. Inc.
    Ph.D., Nobel Laureate, Fred Hutchinson Cancer Research Center member; Professor of Physiology and Biophysics, University of Washington
    Ph.D., American Cancer Society Professor of Genome Sciences and Medical Genetics, University of Washington
    Ph.D., Nobel Laureate, Professor of Biology and member of the Koch Institute, Chair of the advisory board of the MIT Jameel Clinic

European Wellness Signs MOU with Tianyou to Expand Education, Research and Development, and Healthcare in China.

Retrieved on: 
Venerdì, Giugno 23, 2023
EW Group, Partnership, Education, MD, EWA, Medicine, Research, Koch Institute for Integrative Cancer Research, Biology, Organization, The Wells Academy, Patient, MOU, Therapy, Growth, Research institute, CPD, Pharmaceutical industry, European, Immunology

BEIJING, June 23, 2023 /PRNewswire/ -- European Wellness Academy (EWA), the Malaysian educational arm of European Wellness Biomedical Group (EW Group), and Tianyou (Macau) Group Co., have signed a Memorandum of Understanding (MOU) to enhance the education, research and development, and healthcare sectors throughout China.

Key Points: 
  • BEIJING, June 23, 2023 /PRNewswire/ -- European Wellness Academy (EWA), the Malaysian educational arm of European Wellness Biomedical Group (EW Group), and Tianyou (Macau) Group Co., have signed a Memorandum of Understanding (MOU) to enhance the education, research and development, and healthcare sectors throughout China.
  • One of the objectives of this joint effort is the establishment of "European Wellness Centers of Excellence for Biological Regenerative Medicine."
  • The first center will be a European Wellness-Academy and branded integrative medicine, wellness, and aesthetic facility.
  • The second aspect of the partnership is the development of "European Wellness Academy," which will be serving as a biomedical education and training academy for the purpose of achieving professional development, which internationally-accredited European Wellness certification.

European Wellness Signs MOU with Tianyou to Expand Education, Research and Development, and Healthcare in China.

Retrieved on: 
Venerdì, Giugno 23, 2023
EW Group, Partnership, Education, MD, EWA, Medicine, Research, Multimedia, Koch Institute for Integrative Cancer Research, Biology, Organization, The Wells Academy, Patient, MOU, Therapy, Growth, Research institute, CPD, Pharmaceutical industry, European, Immunology

BEIJING, June 23, 2023 /PRNewswire/ -- European Wellness Academy (EWA), the Malaysian educational arm of European Wellness Biomedical Group (EW Group), and Tianyou (Macau) Group Co., have signed a Memorandum of Understanding (MOU) to enhance the education, research and development, and healthcare sectors throughout China.

Key Points: 
  • BEIJING, June 23, 2023 /PRNewswire/ -- European Wellness Academy (EWA), the Malaysian educational arm of European Wellness Biomedical Group (EW Group), and Tianyou (Macau) Group Co., have signed a Memorandum of Understanding (MOU) to enhance the education, research and development, and healthcare sectors throughout China.
  • One of the objectives of this joint effort is the establishment of "European Wellness Centers of Excellence for Biological Regenerative Medicine."
  • The first center will be a European Wellness-Academy and branded integrative medicine, wellness, and aesthetic facility.
  • The second aspect of the partnership is the development of "European Wellness Academy," which will be serving as a biomedical education and training academy for the purpose of achieving professional development, which internationally-accredited European Wellness certification.

Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

Retrieved on: 
Giovedì, Giugno 1, 2023
Convention center, Boston Convention and Exhibition Center, Koch Institute, SAN, Conference, Koch Institute for Integrative Cancer Research, EDT, MIT

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:

Key Points: 
  • SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:
    BIO International Convention, being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, MA.
  • Ms. Johnson will provide a corporate overview on Tuesday, June 6th at 12:00 p.m. EDT.
  • Longwood Healthcare Leaders Spring 2023 MIT Conference, being held June 7-8, 2023 at the Koch Institute at MIT, Cambridge, MA.
  • Ms. Johnson will participate in a panel discussion on Thursday, June 8th at 3:40 p.m. EDT:

Break Through Cancer Launches Two TeamLabs Targeting Acute Myelogenous Leukemia (AML)

Retrieved on: 
Martedì, Maggio 16, 2023
Central nervous system, Bone marrow, Research, MIT, Thought, AML, Trust, Spleen, Physician, Lymph, OnlyOffice, Liver, Koch Institute for Integrative Cancer Research, TeamLab (art collective), Recurrence, Clonal hematopoiesis, Massachusetts Institute of Technology School of Science, Pharmaceutical industry, Cancer, Biology

CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Break Through Cancer, a collaborative medical research organization empowering researchers and physicians from top cancer research institutions to intercept and find cures for several of the world's deadliest cancers, is announcing the launch of the Targeting Clonal Hematopoiesis to Prevent AML TeamLab and the Eradicating Minimal Residual Disease in AML TeamLab.

Key Points: 
  • AML accounts for 1% of all cancers and has a five-year survival rate of less than 30%.
  • Break Through Cancer TeamLabs look beyond conventional therapies, utilizing new strategies, structures, and thinking from across disciplines.
  • "The TeamLabs approach that Break Through Cancer is pioneering promises 'radical collaboration' for cancer treatment discovery while affording unprecedented synergies among our dispersed scientific teams," said Tyler Jacks, Ph.D., President of Break Through Cancer.
  • "Ultimately, our TeamLab will identify new molecular targets for treatment strategies that we hope will prevent the development and recurrence of AML," said Dr. Jacks.

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Retrieved on: 
Martedì, Aprile 25, 2023
The Ride to Conquer Cancer, Sidney Kimmel, Sreyashi Jhumki Basu, GBM, Research group, Ovarian cancer, Pancreatic cancer, Cancer, Research, Koch Institute, MIT, CD73, Genomics, The Institute, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Associate, Science, Physician, Sidney Kimmel Comprehensive Cancer Center, University, Escape Room, Drug development, Knowledge, Koch Institute for Integrative Cancer Research, TeamLab (art collective), Johns Hopkins, Break, Tumor microenvironment, Nanobiotechnology, Vaccine, Medical imaging

CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.

Key Points: 
  • They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.
  • The Break Through Cancer Scientists were carefully selected based on their expertise in early diagnostics, single cell genomics data and materials science, and specific types of cancer.
  • "These newly named Break Through Cancer Scientists have cultivated stellar reputations and demonstrated outstanding success in working across scientific disciplines to establish a collaborative environment.
  • A Research Group Leader at The University of Texas MD Anderson Cancer Center's Pancreatic Cancer Research Center, Paola leads innovative research on patient-derived models and biospecimens.